---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044930"
form_type: "8-K"
ticker: "AZTR"
cik: "0001701478"
company_name: "Azitra, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:58:44.422470+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Azitra Q3 net loss narrows to $1.0M; pipeline advances with ATR-12 dosing, ATR-04 IND clearance

## Summary
- Net loss of $1.0M in Q3 2024 vs $1.9M in Q3 2023; cash and equivalents $7.3M as of Sept 30, 2024.
- R&D expenses rose to $1.0M from $0.5M; G&A steady at $1.9M; service revenue was $0 vs $310K.
- Completed $10M follow-on offering; dosed first Netherton syndrome patient with ATR-12 in Phase 1b trial.
- Received IND clearance and Fast Track designation from FDA for ATR-04 to treat EGFRi-associated rash.
- Anticipates initial safety data from ATR-12 trial in Q1 2025; first ATR-04 patient dosed in Q1 2025; topline data YE 2025.

## SEC filing metadata
- accession: 0001493152-24-044930
- form_type: 8-K
- ticker: AZTR
- cik: 0001701478
- company_name: Azitra, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701478/000149315224044930/0001493152-24-044930-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701478/000149315224044930/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044930
- JSON: https://secwatch.observer/filing/0001493152-24-044930.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044930.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.